Madrigal Pharmaceuticals (MDGL) Interest & Investment Income (2016 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Interest & Investment Income of $7.1 million for Q2 2026, down 13.65% year-over-year from $8.2 million in Q2 2025, and down 13.82% quarter-over-quarter from $8.2 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Interest & Investment Income (2016 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Interest & Investment Income for 11 consecutive years, with $7.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income fell 13.65% year-over-year to $7.1 million; the TTM figure through Jun 2026 stood at $35.1 million (down 15.78% YoY), while the FY2025 annual figure was $37.4 million, down 19.91% from the prior year.
- Interest & Investment Income declined to $7.1 million in Q2 2026 per MDGL's latest filing, from $8.2 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $14.2 million in Q2 2024 and bottomed at $69000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $6.7 million across 5 years, with a median of $8.2 million in 2025.
- Annual changes were most pronounced in 2022 — Interest & Investment Income tumbled 56.88% — and 2023, when it soared 5372.46%.
- Madrigal Pharmaceuticals' Interest & Investment Income stood at $1.1 million in 2022, then surged by 732.06% to $9.0 million in 2023, then climbed by 23.75% to $11.1 million in 2024, then declined by 14.62% to $9.5 million in 2025, then declined by 24.9% to $7.1 million in 2026.
- Business Quant data shows MDGL's Interest & Investment Income at $7.1 million in Q2 2026, $8.2 million in Q1 2026, and $9.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 7.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.10 Mn |
| Mar 31, 2026 | 8.24 Mn |
| Dec 31, 2025 | 9.46 Mn |
| Sep 30, 2025 | 10.31 Mn |
| Jun 30, 2025 | 8.23 Mn |
| Mar 31, 2025 | 9.37 Mn |
| Dec 31, 2024 | 11.08 Mn |
| Sep 30, 2024 | 13.02 Mn |
| Jun 30, 2024 | 14.22 Mn |
| Mar 31, 2024 | 8.33 Mn |
| Dec 31, 2023 | 8.95 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 3.55 Mn |
| Mar 31, 2023 | 3.78 Mn |
| Dec 31, 2022 | 1.08 Mn |
| Sep 30, 2022 | 717,000.00 |
| Jun 30, 2022 | 323,000.00 |
| Mar 31, 2022 | 69,000.00 |
| Dec 31, 2021 | 52,000.00 |
| Sep 30, 2021 | 60,000.00 |